Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Compare

981 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APLS Analyst Ratings

Moderate Buy

9 Buy

6 Hold

1 Sell

Based on 16 analysts giving stock ratings to

Apellis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$33.07

▲(64.53% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $33.07 with a high forecast of $52.00 and a low forecast of $18.00. The average price target represents a 64.53% change from the last price of $20.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","53":"$53","25.25":"$25.3","34.5":"$34.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.07,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25.25,34.5,43.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.47,23.818461538461538,26.166923076923077,28.515384615384612,30.863846153846154,33.21230769230769,35.560769230769225,37.90923076923077,40.25769230769231,42.606153846153845,44.95461538461538,47.30307692307692,49.65153846153846,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.47,22.36230769230769,23.254615384615384,24.146923076923077,25.03923076923077,25.931538461538462,26.823846153846155,27.716153846153844,28.60846153846154,29.50076923076923,30.393076923076926,31.285384615384615,32.17769230769231,{"y":33.07,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.47,21.20307692307692,20.936153846153847,20.66923076923077,20.40230769230769,20.135384615384616,19.86846153846154,19.60153846153846,19.334615384615383,19.067692307692308,18.80076923076923,18.533846153846156,18.266923076923078,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$33.07

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Douglas Tsao

H.C. Wainwright

$19.81→$45

Buy

123.88%

Upside

Reiterated

11/14/25

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

11/10/25

Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis PharmaceuticalsWe attended the Nephrology (ASN) 2025 Kidney Week annual meeting, where Apellis and Novartis (NVS $126.35) presented additional analyses and long-term results from Empaveli (pegcetacoplan) and Fabhalta (iptacopan) for the treatment of C3G and/or IC-MPGN. Overall, the results continue to support the clinically meaningful efficacy of both products in their approved indications, with their treatment effects sustained over long-term treatment, and we believe the data continue to support a potentially best-in-class profile for Empaveli. Key takeaways include: Proteinuria remission (≤0.5 g/g) and normalization (≤0.2 g/g) achieved with pegcetacoplan at week 26 is sustained through 52 weeks of treatment.

Andy Chen

Wolfe Research

―

Hold

―

Initiated

11/05/25

Hold Rating on Apellis Pharmaceuticals: Balancing Stagnant Revenue Growth and Market ChallengesWe would revise this thesis if Apellis plans a more near-term catalyst in 2026 (interim readout?). This would signal confidence in earlier separation from the sham relative to mono Syfovre.

Anupam Rama

J.P. Morgan

$40→$36

Buy

79.10%

Upside

Reiterated

11/05/25

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

Phil Nadeau

TD Cowen

$45

Buy

123.88%

Upside

Reiterated

11/04/25

TD Cowen Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

Graig Suvannavejh

Mizuho Securities

$24→$19

Hold

-5.47%

Downside

Reiterated

11/03/25

Apellis price target raised to $24 from $22 at MizuhoApellis price target raised to $24 from $22 at Mizuho

Yigal Nochomovitz

Citi

$52→$45

Buy

123.88%

Upside

Reiterated

10/31/25

Apellis price target lowered to $45 from $52 at CitiApellis price target lowered to $45 from $52 at Citi

Colleen M. Kusy

Robert W. Baird

$50→$52

Buy

158.71%

Upside

Reiterated

10/31/25

Apellis price target raised to $52 from $50 at BairdApellis price target raised to $52 from $50 at Baird

Joseph Stringer

Needham

$29

Buy

44.28%

Upside

Reiterated

10/30/25

Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis PharmaceuticalsWe estimate Syfovre holds ~55% (down from ~58% in 2Q25) revenue-based market share over Izervay. Mgmt reiterated cash on hand plus product sales is sufficient to get to sustainable profitability. This morning, Astellas significantly lowered their revenue forecast for ~$550M (was ~$750M), which we see as a negative readthrough to Syfovre and the overall GA market. That, coupled with the ongoing co-pay issues, is putting significant pressure on APLS shares today in our view.

Tazeen Ahmad

Bank of America Securities

$29→$27

Hold

34.33%

Upside

Reiterated

10/30/25

Apellis price target lowered to $27 from $29 at BofAApellis price target lowered to $27 from $29 at BofA

Lisa Walter

RBC Capital

$22

Hold

9.45%

Upside

Reiterated

10/30/25

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

Judah Frommer

Morgan Stanley

$26→$25

Hold

24.38%

Upside

Reiterated

10/30/25

Apellis Pharmaceuticals (APLS) Receives a Hold from Morgan Stanley

Derek Archila

Wells Fargo

$29→$32

Buy

59.20%

Upside

Upgraded

10/15/25

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS), Impedimed Limited (Other OTC: IPDQF) and Humana (NYSE: HUM)Wells Fargo upgrades APLS to Overweight. PT 32 from 29. Analyst Derek Archila.

Biren Amin

Piper Sandler

$28

Hold

39.30%

Upside

Reiterated

10/06/25

Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

Salveen Richter

Goldman Sachs

$18

Sell

-10.45%

Downside

Downgraded

09/26/25

Cautious Outlook on Apellis Pharmaceuticals Amid Market Challenges and Financial ConstraintsApellis Pharmaceuticals (APLS): Monitoring risks to the outlook; Downgrade to Sell 26 September 2025 | 5:01AM EDT We downgrade APLS from Neutral to Sell with a lowered price target of $18.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Douglas Tsao

H.C. Wainwright

$19.81→$45

Buy

123.88%

Upside

Reiterated

11/14/25

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

11/10/25

Andy Chen

Wolfe Research

―

Hold

―

Initiated

11/05/25

Anupam Rama

J.P. Morgan

$40→$36

Buy

79.10%

Upside

Reiterated

11/05/25

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

Phil Nadeau

TD Cowen

$45

Buy

123.88%

Upside

Reiterated

11/04/25

TD Cowen Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

Graig Suvannavejh

Mizuho Securities

$24→$19

Hold

-5.47%

Downside

Reiterated

11/03/25

Apellis price target raised to $24 from $22 at MizuhoApellis price target raised to $24 from $22 at Mizuho

Yigal Nochomovitz

Citi

$52→$45

Buy

123.88%

Upside

Reiterated

10/31/25

Apellis price target lowered to $45 from $52 at CitiApellis price target lowered to $45 from $52 at Citi

Colleen M. Kusy

Robert W. Baird

$50→$52

Buy

158.71%

Upside

Reiterated

10/31/25

Apellis price target raised to $52 from $50 at BairdApellis price target raised to $52 from $50 at Baird

Joseph Stringer

Needham

$29

Buy

44.28%

Upside

Reiterated

10/30/25

Tazeen Ahmad

Bank of America Securities

$29→$27

Hold

34.33%

Upside

Reiterated

10/30/25

Apellis price target lowered to $27 from $29 at BofAApellis price target lowered to $27 from $29 at BofA

Lisa Walter

RBC Capital

$22

Hold

9.45%

Upside

Reiterated

10/30/25

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

Judah Frommer

Morgan Stanley

$26→$25

Hold

24.38%

Upside

Reiterated

10/30/25

Apellis Pharmaceuticals (APLS) Receives a Hold from Morgan Stanley

Derek Archila

Wells Fargo

$29→$32

Buy

59.20%

Upside

Upgraded

10/15/25

Biren Amin

Piper Sandler

$28

Hold

39.30%

Upside

Reiterated

10/06/25

Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

Salveen Richter

Goldman Sachs

$18

Sell

-10.45%

Downside

Downgraded

09/26/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apellis Pharmaceuticals

1 Month

xxx

Success Rate

22/35 ratings generated profit

Average Return

+5.55%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 62.86% of your transactions generating a profit, with an average return of +5.55% per trade.

3 Months

xxx

Success Rate

18/29 ratings generated profit

Average Return

+4.42%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.07% of your transactions generating a profit, with an average return of +4.42% per trade.

1 Year

Steven SeedhouseCantor Fitzgerald

Success Rate

12/29 ratings generated profit

Average Return

-3.90%

reiterated a buy rating 2 months ago

Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 41.38% of your transactions generating a profit, with an average return of -3.90% per trade.

2 Years

xxx

Success Rate

15/29 ratings generated profit

Average Return

-1.72%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 51.72% of your transactions generating a profit, with an average return of -1.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APLS has received 14 Buy Ratings, 15 Hold Ratings, and 1 Sell Ratings. APLS average Analyst price target in the past 3 months is 33.07.

Each month's total comprises the sum of three months' worth of ratings.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is -$0.37 with a range of -$0.55 to -$0.16. The previous quarter’s EPS was $1.67. APLS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $200.39M with a range of $184.60M to $232.00M. The previous quarter’s sales results were $458.58M. APLS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?

Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 33.07.

What is APLS’s upside potential, based on the analysts’ average price target?

Apellis Pharmaceuticals Inc has 64.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is APLS a Buy, Sell or Hold?

Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 1 sell ratings.

What is Apellis Pharmaceuticals Inc’s price target?

The average price target for Apellis Pharmaceuticals Inc is 33.07. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $18.00. The average price target represents 64.53% Increase from the current price of $20.1.

What do analysts say about Apellis Pharmaceuticals Inc?

Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of APLS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

APLS Analyst Ratings

APLS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Apellis Pharmaceuticals

APLS Analyst Recommendation Trends

APLS Financial Forecast

APLS Earnings Forecast

APLS Sales Forecast

APLS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts